IMM-2902

N/A

Report date: 2023/04/11 20:00:23

Base Information

Drug NameIMM-2902
Drug Alias NameIMM-2902
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionAnti-HER2Cluster of differentiation 47 inhibitors
TargetsReceptor protein-tyrosine kinase erbB-2Cluster of differentiation 47
Therapy Area/IndicationsSolid tumoursLung NeoplasmsStomach Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursLung NeoplasmsStomach Neoplasms +[4] 
Inactive IndicationsBreast Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A